SANDOZ A/S
CVR: 27744532
Secondary names: DURASCAN A/S, DURASCAN MEDICAL PRODUCTS A/S, HEXAL SCANDINAVIA A/S
Previous names: DURASCAN MEDICAL PRODUCTS A/S
SANDOZ A/S demonstrates a solid financial health with a consistent upward trajectory in revenue, reaching 2.52 billion DKK in 2024, up from 2.29 billion DKK in 2023. However, profit has decreased from 68.5 million DKK in 2023 to 48 million DKK in 2024, indicating potential margin pressures. The company's equity has improved significantly, standing at 577.6 million DKK, reflecting a strong capital position within the pharmaceutical wholesale industry. Despite the recent dip in profitability, SANDOZ A/S maintains a robust revenue growth trend, positioning itself favorably among competitors.
AI-generated summary
Overview
Details
Purpose
Selskabets formål er at drive handel, industri og finansiering samt anden dermed beslægtet virksomhed, herunder at drive virksomhed gennem datterselskaber.
Location
Financials
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 2.5 mia. | 48 mio. | 1.5 mia. | 577.6 mio. | 106 | |
History
Ownership
Management
Directors
Board
Production units (9)
Similar companies
Companies in the same industry and area